-
NIH researchers conduct first genomic survey of human skin fungal diversity; Location on the body surface determines fungal composition with the greatest diversity on feet
NIH Press Release
(Posted: 05/22/2013) - Fungal infections of the skin affect 29 million people in the United States. In the first study of human fungal skin diversity, National Institutes of Health researchers sequenced the DNA of fungi that thrive at different skin sites of healthy adults to define the normal populations across the skin topography and to provide a framework for investigating fungal skin conditions.
-
Experimental drug beneficial in NIH trial to treat a rare sarcoma
NCI Press Release
(Posted: 05/02/2013) - Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib. The results from this largest clinical trial on ASPS to date were published in the Journal of Clinical Oncology
-
TCGA researchers identify potential drug targets, markers for leukemia risk; New study reveals relatively few mutations in AML genomes
NCI Press Release
(Posted: 05/01/2013) - Investigators for The Cancer Genome Atlas (TCGA) Research Network have detailed and broadly classified the genomic alterations that frequently underlie the development of acute myeloid leukemia (AML), a deadly cancer of the blood and bone marrow. Their work paints a picture of a cancer marked by relatively few mutations compared to other types of cancer occurring in adults.
-
Study establishes basis for genomic classification of endometrial cancers; proper categorization is important for choosing the best treatment
NCI Press Release
(Posted: 05/01/2013) - A comprehensive genomic analysis of nearly 400 endometrial tumors suggests that certain molecular characteristics – such as the frequency of mutations – could complement current pathology methods and help distinguish between principal types of endometrial tumors, as well as provide insights into potential treatment strategies.
-
A drug target that stimulates development of healthy stem cells
NCI News Note
(Posted: 04/17/2013) - Scientists have overcome a major impediment to the development of effective stem cell therapies by studying mice that lack CD47, a protein found on the surface of both healthy and cancer cells. They discovered that cells obtained from the lungs of CD47-deficient mice, but not from ordinary mice that have the CD47 gene, multiplied in a culture dish and spontaneously converted into stem cells
-
Testing lung cancer drugs and therapies in mice
NCI News Note
(Posted: 04/15/2013) - National Cancer Institute (NCI) investigators have designed a genetically engineered mouse for use in the study of human lung squamous cell carcinoma (SCC). SCC is a type of non-small cell lung carcinoma, one of the most common types of lung cancer, with a five-year survival rate of about 15 percent.
-
NIH trial shows promising results in treating a lymphoma in young people
NCI Press Release
(Posted: 04/10/2013) - Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to clinical trial results.
-
A tumor suppressor is identified as an inhibitor of inflammatory pathways
NCI News Note
(Posted: 04/09/2013) - Scientists at NCI have found that a protein, FBXW7, which acts as a tumor suppressor, is also important for the reduction in strength of inflammatory pathways. It has long been recognized that a complex interaction exists between cancer causing mechanisms and inflammation.
-
Cancer immunotherapy in children: How does it differ from approaches in adults?
NCI Perspective
(Posted: 04/08/2013) - More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population. Depicted are members of NCI’s Pediatric Oncology Branch. From left: Drs. Crystal Mackall, Daniel Lee, and Alan Wayne
-
Mitochondrial chaperones may represent novel targets for developing anti-cancer drugs
NCI News Note
(Posted: 04/01/2013) - Scientists at NCI have found that a mitochondrial chaperone protein, TRAP1, may act indirectly as a tumor suppressor as well as a novel target for developing anti-cancer drugs. Chaperone proteins, such as TRAP1, help other proteins adapt to stress, but scientists are coming to appreciate that they have other functions as well, such as, in this case, affecting tumor development.
